Jeff Yass’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-1,259
| Closed | -$9.38K | – | 12750 |
|
|
2024
Q3 | $9.74K | Sell |
1,259
-27,713
| -96% | -$167K | ﹤0.01% | 11725 |
|
|
2024
Q2 | $174K | Buy |
28,972
+23,640
| +443% | +$180K | ﹤0.01% | 10539 |
|
|
2024
Q1 | $48.1K | Sell |
5,332
-3,209
| -38% | -$29.2K | ﹤0.01% | 11577 |
|
|
2023
Q4 | $80.9K | Buy |
8,541
+2,959
| +53% | +$26K | ﹤0.01% | 11470 |
|
|
2023
Q3 | $66.4K | Sell |
5,582
-2,189
| -28% | -$38.8K | ﹤0.01% | 11156 |
|
|
2023
Q2 | $190K | Sell |
7,771
-10,501
| -57% | -$273K | ﹤0.01% | 10326 |
|
|
2023
Q1 | $572K | Buy |
18,272
+14,730
| +416% | +$852K | ﹤0.01% | 8242 |
|
|
2022
Q4 | $249K | Sell |
3,542
-5,720
| -62% | -$424K | ﹤0.01% | 9556 |
|
|
2022
Q3 | $797K | Sell |
9,262
-1,830
| -16% | -$178K | ﹤0.01% | 7234 |
|
|
2022
Q2 | $917K | Buy |
11,092
+4,491
| +68% | +$396K | ﹤0.01% | 6746 |
|
|
2022
Q1 | $1.1M | Buy |
6,601
+1,323
| +25% | +$190K | ﹤0.01% | 6872 |
|
|
2021
Q4 | $882K | Buy |
+5,278
| New | +$596K | ﹤0.01% | 7621 |
|
|
2021
Q2 | – | Sell |
-3,040
| Closed | -$181K | – | 12949 |
|
|
2021
Q1 | $181K | Buy |
3,040
+1,527
| +101% | +$89.3K | ﹤0.01% | 11505 |
|
|
2020
Q4 | $79K | Sell |
1,513
-144
| -9% | -$8.01K | ﹤0.01% | 10598 |
|
|
2020
Q3 | $80K | Buy |
+1,657
| New | +$79.2K | ﹤0.01% | 10037 |
|
|
2020
Q2 | – | Sell |
-1,134
| Closed | -$57.2K | – | 10550 |
|
|
2020
Q1 | $49K | Buy |
+1,134
| New | +$46.1K | ﹤0.01% | 9693 |
|
Jeff Yass's KZR Position: Q4 2024 in Review
Jeff Yass sold out of Kezar Life Sciences (KZR) in Q4 2024, closing a stake of 1,259 shares — an estimated $9.38K sold.
Jeff Yass first reported a position in KZR in Q1 2020 and held it in 16 quarters. The position peaked at $1.1M in Q1 2022. 43 funds tracked by Wall St. Rank hold KZR as of Q4 2024.
- Jeff Yass reported no remaining Kezar Life Sciences position as of Q4 2024 after selling out during the quarter.
- Jeff Yass sold 1,259 Kezar Life Sciences shares in Q4 2024, an estimated $9.38K.
- Jeff Yass first reported a position in Kezar Life Sciences in Q1 2020 and held it in 16 quarters.
- Jeff Yass's Kezar Life Sciences position peaked at $1.1M in Q1 2022.
- 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2024.
Based on Susquehanna International Group's 13F filing for Q4 2024, filed 14 Feb 2025.